미국 - 영어 - NLM (National Library of Medicine)

precision dose inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 10 mg in 5 ml - morphine sulfate oral solution 2 mg/ml and 4 mg/ml is indicated for the management of - adults with acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. - pediatric patients 2 years of age and older with acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. morphine sulfate oral solution 20 mg/ml is indicated for the relief of acute and chronic pain in opioid-tolerant adult patients . limitations of use: because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. morphine sulfate oral solution is contraindic

미국 - 영어 - NLM (National Library of Medicine)

pai holdings, llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 100 mg in 5 ml - morphine sulfate oral solution 20 mg/ml is indicated for the relief of acute and chronic pain in opioid-tolerant adult patients . limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.2)] , reserve morphine sulfate oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. morphine sulfate oral solution is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.4) ]. - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.7) ]. - concurrent use of monoamine oxidase inhibitors (maois) or use of maois

미국 - 영어 - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - buprenorphine (unii: 40d3scr4gz) (buprenorphine - unii:40d3scr4gz) - buprenorphine transdermal system is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. l imitations of use - because of the risks of addiction, abuse and misuse with opioids, even at recommended doses, and because of the greater risk of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve buprenorphine transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - buprenorphine transdermal system is not indicated as an as-needed (prn) analgesic buprenorphine transdermal system is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.3)] - acute or severe bronchial asthma in an unmonitored setting or in the

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml - solution for injection - 10 mg/ml - active: morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml - solution for injection - 100 mg/5ml - active: morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml - solution for injection - 20 mg/ml - active: morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml - solution for injection - 50 mg/5ml - active: morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

미국 - 영어 - NLM (National Library of Medicine)

specgx llc - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz), naloxone hydrochloride dihydrate (unii: 5q187997ee) (naloxone - unii:36b82amq7n) - buprenorphine 2 mg - buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence. buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. buprenorphine and naloxone sublingual tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see warnings and precautions (5.9)] . risk summary the data on use of buprenorphine, one of the active ingredients in buprenorphine and naloxone sublingual tablets, in pregnancy, are limited; however, these data do not indicate  an increased risk of major malformations specifically due to buprenorphine exposure. there are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see data] . observational studies have reported on cong

미국 - 영어 - NLM (National Library of Medicine)

mckesson corporation - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets  are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use morphine sulfate extended-release tablets are contraindicated in patients with: clinical considerations fetal/neonatal adverse reactions prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. observe newborns for symptoms of neonatal opioid withdrawal syndrome, such as poor feeding, diarrhea, irritability, tremor, rigidity, and seizures, and manage accordingly [see warnings and precautions (5.3)]. teratogenic effects (pregnancy category c) there are no adequate and well-controlled studies in pregnant women. morphine sulfate extended-release tablets should be used during pregnancy only if the potential benefit justifies the potential r

미국 - 영어 - NLM (National Library of Medicine)

atlantic biologicals corp. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 20 mg in 5 ml - morphine sulfate oral solution (10 mg per 5 ml and 20 mg per 5 ml) are formulations of morphine, an opioid agonist, indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. morphine sulfate oral solution 100 mg per 5 ml (20 mg/ml) is an opioid analgesic indicated for the relief of moderate to severe acute and chronic pain in opioid-tolerant patients. morphine sulfate oral solution 100 mg per 5 ml (20 mg/ml) may cause fatal respiratory depression when administered to patients not previously exposed to opioids. patients considered to be opioid tolerant are those who are taking at least 60 mg oral morphine per day, or at least 30 mg of oral oxycodone per day, or at least 12 mg hydromorphone per day, or an equianalgesic dose of another opioid, for a week or longer. morphine sulfate is contraindicated in patients with known hypersensitivity to morphine, morphine salts, or any components of the product. morphine sulfate is contraindicated in patients